|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| Sponsored by: |
R. Nandan M.D. Incorporated |
| Information provided by: | National Cancer Institute (NCI) |
| ClinicalTrials.gov Identifier: | NCT00005825 |
Purpose
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase II trial to study the effectiveness of combination chemotherapy in treating patients who have stage IIIB or stage IV non-small cell lung cancer.
| Condition | Intervention | Phase |
|
Lung Cancer |
Drug: cisplatin Drug: mitomycin C Drug: tretinoin Drug: vinorelbine ditartrate |
Phase II |
| MedlinePlus related topics: | Cancer Lung Cancer |
| Drug Information available for: | Cisplatin Vinorelbine Vinorelbine tartrate Tretinoin Mitomycin Mitomycins |
| Study Type: | Interventional |
| Study Design: | Treatment |
| Official Title: | Trans Retinoic Acid (Vesanoid) With Chemotherapy in Non-Small Cell Lung Cancer |
| Study Start Date: | September 1998 |
OBJECTIVES:
OUTLINE: Patients receive tretinoin orally twice daily for 4 days starting days 1 and 8; cisplatin IV over 2 hours and vinorelbine IV on days 1 and 8; and mitomycin IV (courses 1 and 3) on day 1. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Patients are followed for survival.
PROJECTED ACCRUAL: At total of 15-46 patients will be accrued for this study.
Eligibility
| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
Age:
Performance status:
Life expectancy:
Hematopoietic:
Hepatic:
Renal:
Cardiovascular:
Other:
PRIOR CONCURRENT THERAPY:
Biologic therapy:
Chemotherapy:
Endocrine therapy:
Radiotherapy:
Surgery:
Contacts and Locations| United States, California | |||||
| Rajendra Prasad M.D., Inc. | |||||
| Lakewood, California, United States, 90712 | |||||
| R. Nandan M.D. Incorporated |
| Study Chair: | Raghu Nandan, MD | R. Nandan M.D. Incorporated |
More Information
Clinical trial summary from the National Cancer Institute's PDQ® database 
  |
| Study ID Numbers: | CDR0000067837, NANDAN-VES-024, NCI-V00-1587 |
| First Received: | June 2, 2000 |
| Last Updated: | July 23, 2008 |
| ClinicalTrials.gov Identifier: | NCT00005825 |
| Health Authority: | United States: Federal Government |
|
|
|
|
|